SEC Comment Letter for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA, TEVJF) (CIK 0000818686) (TEVA) — Jul 7, 2014
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA, TEVJF) (CIK 0000818686)
Date: July 7, 2014 · CIK: 0000818686 · Accession: 0000000000-14-034014
AI Filing Summary & Sentiment
File numbers found in text: 001-16174
Letter
July 7, 2014 Via E-mail Mr. Eyal Desheh Executive Vice President and Chief Financial Officer Teva Pharmaceutical Industries Ltd. 5 Basel Street P.O. Box 3190 Petach Tivka 4951033 Israel
Re: Teva Pharmaceutical Industries Ltd. Form 20-F for the Fiscal Year Ended December 31, 2013 Filed February 10, 2014 File No . 001-16174
Dear Mr. Desheh :
We have completed our review of your filing. We remind you that our comment or changes to disclo sure in response to our comment do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert the staff comment as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing s to be certain that the filing s include the information the Securities Exchange Act o f 1934 and all applicable rules require.
Sincerely,
/s/ Jeffrey P. Riedler
Show Raw Text
July 7, 2014 Via E-mail Mr. Eyal Desheh Executive Vice President and Chief Financial Officer Teva Pharmaceutical Industries Ltd. 5 Basel Street P.O. Box 3190 Petach Tivka 4951033 Israel Re: Teva Pharmaceutical Industries Ltd. Form 20-F for the Fiscal Year Ended December 31, 2013 Filed February 10, 2014 File No . 001-16174 Dear Mr. Desheh : We have completed our review of your filing. We remind you that our comment or changes to disclo sure in response to our comment do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert the staff comment as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing s to be certain that the filing s include the information the Securities Exchange Act o f 1934 and all applicable rules require. Sincerely, /s/ Jeffrey P. Riedler Jeffrey Riedler Assistant Director